Peroxisome proliferator-activated receptors gama ameliorates liver fibrosis in non-alcoholic fatty liver disease by inhibiting TGF-β/Smad signaling activation

Abstract

Background

Nonalcoholic fatty liver disease (NAFLD) is a chronic condition characterized by a progressive decline in liver function, leading to disruptions in liver integrity and metabolic function, resulting in lipid deposition and excessive accumulation of extracellular matrix (ECM). The pathogenesis of NAFLD is complex and not yet fully understood, contributing to the absence of specific therapeutic strategies. Peroxisome proliferator-activated receptor gamma (PPARγ) is a ligand-activated transcription factor pivotal in regulating lipid and glucose metabolism. However, the impacts of PPARγ on NAFLD remains insufficiently explored. Thus, this study aimed to investigate the role of PPARγ in NAFLD and its underlying molecular mechanisms.

Methods

Chemical detection kits were utilized to quantify collagen content, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) level variations. Quantitative real-time polymerase chain reaction (qRT-PCR) was employed to assess alterations in extracellular matrix-related genes and inflammatory response genes in liver tissue and HepG2 cells, while western blotting was conducted to analyze the levels of both PPARγ and the TGF-β/Smad signaling pathway.

Results

Our findings unveiled significantly reduced PPARγ expression in a rat model of NAFLD, leading to subsequent activation of the TGF-β/Smad signaling pathway. Furthermore, PPARγ activation effectively mitigated NAFLD progression by inhibiting inflammation and fibrosis-related gene expression and collagen production. On a cellular level, PPARγ activation was found to inhibit the expression of extracellular matrix-related genes such as matrix metalloproteinase 2 (MMP2) and matrix metalloproteinase 9 (MMP9), along with inflammatory response genes interleukin (IL)-1β and IL-6. Additionally, PPARγ activation led to a significant decrease in the levels of ALT and AST. At the molecular level, PPARγ notably down-regulated the TGF-β/Smad signaling pathway, which is known to promote liver fibrosis.

Conclusion

These groundbreaking findings underscore PPARγ activation as a promising therapeutic approach to delay NAFLD progression by targeting the TGF-β/Smad signaling pathway in hepatic cells. This highlights the potential of PPARγ as a promising therapeutic target for NAFLD management in clinical settings.

Keywords

NAFLD / PPARγ / TGF-β/Smad; / liver fibrosis / NAFLD / PPARγ / TGF-β/Smad; / liver fibrosis

References

[1]	Le M H, Le D M, Baez T C, et al.Global incidence of non-alcoholic fatty liver disease: A systematic review and meta-analysis of 63 studies and 1, 201, 807 persons. J Hepatol, 2023; 79(2): 287-295. doi: 10.1016/j.jhep.2023.03.040
[2]	Chen H, Zhan Y, Zhang J, et al.The global, regional, and national burden and trends of NAFLD in 204 Countries and territories: an analysis from global burden of disease 2019. JMIR Public Health Surveill, 2022; 8(12): e34809. doi: 10.2196/34809
[3]	Xia M, Sun X, Zheng L, et al.Regional difference in the susceptibility of non-alcoholic fatty liver disease in China. BMJ Open Diabetes Res Care, 2020; 8(1): e001311. doi: 10.1136/bmjdrc-2020-001311
[4]	Liu S, Liu Y, Wan B, et al.Association between vitamin D status and non-alcoholic fatty liver disease: a population-based study. J Nutr Sci Vitaminol (Tokyo), 2019; 65: 303-308. doi: 10.3177/jnsv.65.303
[5]	Jain R, Wade G, Ong I, et al.Determination of tissue contributions to the circulating lipid pool in cold exposure via systematic assessment of lipid profiles. J Lipid Res, 2022; 63(7): 100197. doi: 10.1016/j.jlr.2022.100197
[6]	Su D, Zhou T, Wang Y, et al.Cold exposure regulates hepatic glycogen and lipid metabolism in newborn goats. Int J Mol Sci, 2023; 24(18): 14330. doi: 10.3390/ijms241814330
[7]	Heda R, Yazawa M, Shi M, et al.Non-alcoholic fatty liver and chronic kidney disease: Retrospect, introspect, and prospect. World J Gastroenterol, 2021; 27(17): 1864-1882. doi: 10.3748/wjg.v27.i17.1864
[8]	Wang S, Tang C, Zhao H, et al.Network pharmacological analysis and experimental validation of the mechanisms of action of Si-Ni-San against liver fibrosis. Front Pharmacol, 2021; 12: 656115. doi: 10.3389/fphar.2021.656115
[9]	Wei M, Yan X, Xin X, et al.Hepatocyte-specific Smad4 deficiency alleviates liver fibrosis via the p38/p65 pathway. Int J Mol Sci, 2022; 23(19): 11696. doi: 10.3390/ijms231911696
[10]	Li Z, Wang Z, Dong F, et al.Germacrone attenuates hepatic stellate cells activation and liver fibrosis via regulating multiple signaling pathways. Front Pharmacol, 2021; 12: 745561. doi: 10.3389/fphar.2021.745561
[11]	Yuan S, Wei C, Liu G, et al.Sorafenib attenuates liver fibrosis by triggering hepatic stellate cell ferroptosis via HIF-1alpha/SLC7A11 pathway. Cell Prolif, 2022; 55(1): e13158. doi: 10.1111/cpr.13158
[12]	Seo H Y, Lee S H, Han E, et al.Evogliptin directly inhibits inflammatory and fibrotic signaling in isolated liver cells. Int J Mol Sci, 2022; 23(19): 11636. doi: 10.3390/ijms231911636
[13]	Song Y, Wei J, Li R, et al.Tyrosine kinase receptor B attenuates liver fibrosis by inhibiting TGF-beta/SMAD signaling. Hepatology, 2023; 78(5): 1433-1447. doi: 10.1097/HEP.0000000000000319
[14]	Vallee A, Vallee J N, Lecarpentier Y.PPARgamma agonists: potential treatment for autism spectrum disorder by inhibiting the canonical WNT/beta-catenin pathway. Mol Psychiatry, 2019; 24(5): 643-652. doi: 10.1038/s41380-018-0131-4
[15]	Khan R S, Bril F, Cusi K, et al.Modulation of insulin resistance in nonalcoholic fatty liver disease. Hepatology, 2019; 70(2): 711-724. doi: 10.1002/hep.30429
[16]	Trauner M, Fuchs C D.Novel therapeutic targets for cholestatic and fatty liver disease. Gut, 2022; 71(1): 194-209. doi: 10.1136/gutjnl-2021-324305
[17]	Snyder H S, Sakaan S A, March K L, et al.Non-alcoholic fatty liver disease: a review of anti-diabetic pharmacologic therapies. J Clin Transl Hepatol, 2018; 6(2): 168-174. doi: 10.14218/JCTH.2017.00050
[18]	Chang E, Park C Y, Park S W.Role of thiazolidinediones, insulin sensitizers, in non-alcoholic fatty liver disease. J Diabetes Investig, 2013; 4(6): 517-524. doi: 10.1111/jdi.12107
[19]	Li J, Gong L, Zhang R, et al.Fibroblast growth factor 21 inhibited inflammation and fibrosis after myocardial infarction via EGR1. Eur J Pharmacol, 2021; 910: 174470. doi: 10.1016/j.ejphar.2021.174470
[20]	Zhang Q, Chen X, Hu Y, et al.BIRC5 inhibition is associated with pyroptotic cell death via Caspase3-GSDME pathway in lung adenocarcinoma cells. Int J Mol Sci, 2023; 24(19): 14663. doi: 10.3390/ijms241914663
[21]	Li J, Li Y, Liu Y, et al.Fibroblast growth factor 21 ameliorates Na(V)1.5 and Kir2.1 channel dysregulation in human AC16 cardiomyocytes. Front Pharmacol, 2021; 12: 715466. doi: 10.3389/fphar.2021.715466
[22]	Li J, Xu C, Liu Y, et al.Fibroblast growth factor 21 inhibited ischemic arrhythmias via targeting miR-143/EGR1 axis. Basic Res Cardiol, 2020; 115(2): 9. doi: 10.1007/s00395-019-0768-4
[23]	Zhou Q Y, Yang H M, Liu J X, et al.MicroRNA-497 induced by Clonorchis sinensis enhances the TGF-beta/Smad signaling pathway to promote hepatic fibrosis by targeting Smad7. Parasit Vectors, 2021; 14(1): 472. doi: 10.1186/s13071-021-04972-3
[24]	Ganai A A, Husain M.Genistein attenuates D-GalN induced liver fibrosis/chronic liver damage in rats by blocking the TGF-beta/Smad signaling pathways. Chem Biol Interact, 2017; 261: 80-85. doi: 10.1016/j.cbi.2016.11.022
[25]	Porcuna J, Minguez-Martinez J and Ricote M. The PPARalpha and PPARgamma epigenetic landscape in cancer and immune and metabolic disorders. Int J Mol Sci, 2021; 22(19): 10573. doi: 10.3390/ijms221910573
[26]	Hendawy O, Gomaa H A M, Hussein S, et al. Cold-pressed raspberry seeds oil ameliorates high-fat diet triggered non-alcoholic fatty liver disease. Saudi Pharm J, 2021; 29(11): 1303-1313. doi: 10.1016/j.jsps.2021.09.014
[27]	Wu X, Cheng B, Guo X, et al.PPARalpha/gamma signaling pathways are involved in Chlamydia pneumoniae-induced foam cell formation via upregulation of SR-A1 and ACAT1 and downregulation of ABCA1/G1. Microb Pathog, 2021; 161(Pt B): 105284. doi: 10.1016/j.micpath.2021.105284
[28]	Shan S, Zhou J, Yin R, et al.Millet bran protein hydrolysate displays the anti-non-alcoholic fatty liver disease effect via activating peroxisome proliferator-activated receptor gamma to restrain fatty acid uptake. J Agric Food Chem, 2023; 71(3): 1628-1642. doi: 10.1021/acs.jafc.2c08169
[29]	He J, Hong B, Bian M, et al.Docosahexaenoic acid inhibits hepatic stellate cell activation to attenuate liver fibrosis in a PPARgamma-dependent manner. Int Immunopharmacol, 2019; 75: 105816. doi: 10.1016/j.intimp.2019.105816
[30]	Fiorucci S, Distrutti E.Linking liver metabolic and vascular disease via bile acid signaling. Trends Mol Med, 2022; 28(1): 51-66. doi: 10.1016/j.molmed.2021.10.005
[31]	Kim E R, Park J S, Kim J H, et al.A GLP-1/GLP-2 receptor dual agonist to treat NASH: targeting the gut-liver axis and microbiome. Hepatology, 2022; 75(6): 1523-1538. doi: 10.1002/hep.32235
[32]	Brougham-Cook A, Jain I, Kukla D A, et al.High throughput interrogation of human liver stellate cells reveals microenvironmental regulation of phenotype. Acta Biomater, 2022; 138: 240-253. doi: 10.1016/j.actbio.2021.11.015
[33]	Wu G, Liu Y, Feng W, et al.Hypoxia-induced adipose lipolysis requires fibroblast growth factor 21. Front Pharmacol, 2020; 11: 1279. doi: 10.3389/fphar.2020.01279
[34]	Chojkier M, Lyche K D, Filip M.Increased production of collagen in vivo by hepatocytes and nonparenchymal cells in rats with carbon tetrachloride-induced hepatic fibrosis. Hepatology, 1988; 8(4): 808-814. doi: 10.1002/hep.1840080419
[35]	Wehrhan F, Hyckel P, Guentsch A, et al.Bisphosphonate-associated osteonecrosis of the jaw is linked to suppressed TGFbeta1-signaling and increased Galectin-3 expression: a histological study on biopsies. J Transl Med, 2011; 9: 102. doi: 10.1186/1479-5876-9-102
[36]	Hilt Z T, Maurya P, Tesoro L, et al.Beta2M signals monocytes through non-canonical TGFbeta receptor signal transduction. Circ Res, 2021; 128(5): 655-669. doi: 10.1161/CIRCRESAHA.120.317119
[37]	Zhong C, Lin Z, Ke L, et al.Recent research progress (2015-2021) and perspectives on the pharmacological effects and mechanisms of tanshinone IIA. Front Pharmacol, 2021; 12: 778847. doi: 10.3389/fphar.2021.778847
[38]	Tian H, Liu H, Yu J, et al.PHF14 enhances DNA methylation of SMAD7 gene to promote TGF-beta-driven lung adenocarcinoma metastasis. Cell Discov, 2023; 9(1): 41. doi: 10.1038/s41421-023-00528-0